Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
VALID Act of 2023
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
VALID Act of 2023
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2023 · first_quarter · Q1
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
Source: Senate LDA
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); access to clinical laboratory services pursuant to a telehealth visit Saving Access to Laboratory Services Act H.R. 2377/S. 1000,
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); access to clinical laboratory services pursuant to a telehealth visit Saving Access to Laboratory Services Act H.R. 2377/S. 1000,
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Telehealth Extension and Evaluation Act S. 3593, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
Stop COVID–19 Test Surprise Medical Bills Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93), H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
Further Extending Government Funding Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including COVID-19 test coverage and reimbursement, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
Further Extending Government Funding Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
Further Extending Government Funding Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93), H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
Further Extending Government Funding Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
Further Extending Government Funding Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Telehealth Extension and Evaluation Act S. 3593, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including COVID-19 test coverage and reimbursement, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93), H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
COVID Supplemental Appropriations Act, 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Telehealth Extension and Evaluation Act S. 3593, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Tracking COVID–19 Variants Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93), H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
American Data Privacy and Protection Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Telehealth Extension and Evaluation Act S. 3593, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); access to clinical laboratory services pursuant to a telehealth visit Saving Access to Laboratory Services Act H.R. 2377/S. 1000,
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); access to clinical laboratory services pursuant to a telehealth visit, issues related to health care and laboratory workforce shortages; data privacy and protection changes potentially impacting HIPAA-covered entities. Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369.
Policies related to diagnostics and laboratory regulation
Reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2022 · fourth_quarter · Q4
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises, access to clinical laboratory services via telehealth clinical visits. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Consolidated Appropriations Act, 2023, P.L 117-328.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2022 · third_quarter · Q3
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Telehealth Extension and Evaluation Act S. 3593, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Reimbursement and coverage issues for and related to clinical laboratory services, including implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799, Making Continuing Appropriations for Fiscal Year 2023, and for other purposes, H.R. 6833/P.L. 117-180.
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2022 · second_quarter · 2A
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2022 · second_quarter · 2A
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2022 · second_quarter · Q2
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2022 · first_quarter · Q1
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
Reimbursement and coverage issues for and related to clinical laboratory services, including COVID-19 test coverage and reimbursement, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2021 · fourth_quarter · 4A
COVID-19 test coverage and reimbursement
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2021 · fourth_quarter · Q4
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2021 · third_quarter · Q3
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 4128/S. 2209 - VALID Act of 2021, H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, H.R.2144 - Access to Genetic Counselor Services Act of 2021, S.1744 - Genomics Data Security Act, S.1260 - United States Innovation and Competition Act of 2021, H.R.2731 - Endless Frontier Act
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2021 · second_quarter · Q2
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 4128/S. 2209 - VALID Act of 2021, H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, H.R.2144 - Access to Genetic Counselor Services Act of 2021, S.1744 - Genomics Data Security Act, S.1260 - United States Innovation and Competition Act of 2021, H.R.2731 - Endless Frontier Act
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2021 · first_quarter · Q1
COVID-19 test coverage and reimbursement and commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act, H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2020 · fourth_quarter · Q4
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act, H.R.133 Consolidated Appropriations Act, 2021, H.R.8900 Further Continuing Appropriations Act, 2021, and Other Extensions Act, H.R.1520 Further Extension of Continuing Appropriations Act, 2021, H.R. 925 Updated Heroes Act, H.R.8496 SPEEDY COVID-19 Tests Act, S.4198 Affordable Coronavirus Testing Act, S.4740 Public Health Infrastructure Saves Lives Act, H.R.8505 To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes., H.R.8702 Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2020 · third_quarter · Q3
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2020 · second_quarter · Q2
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2020 · first_quarter · Q1
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548).
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2019 · fourth_quarter · Q4
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2019 · third_quarter · Q3
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020, H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act.
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2019 · second_quarter · Q2
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019.
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2019 · first_quarter · Q1
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271).
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · fourth_quarter · Q4
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
SUPPORT for Patients and Communities Act (PL 115-271); role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion; application of anti-kickback laws to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · second_quarter · 2A
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · third_quarter · 3A
H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · third_quarter · Q3
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · second_quarter · Q2
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · first_quarter · Q1
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises and reauthorization of the Pandemic and All Hazards Preparedness Act
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · fourth_quarter · Q4
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · third_quarter · Q3
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · second_quarter · Q2
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; P.L. 115-30, Making further continuing appropriations for fiscal year 2017, and for other purposes; P.L. 115-31, Consolidated Appropriations Act, FY2017; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Acts, 2018; FY2018 White House Budget Proposal.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · first_quarter · Q1
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy.
regulation and oversight of clinical laboratories, including laboratory developed test services; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2016 · fourth_quarter · Q4
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R.34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2016 · third_quarter · 3A
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2016 · third_quarter · Q3
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2016 · second_quarter · Q2
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2016 · first_quarter · 1A
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and FY2017 Agriculture Appropriations.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2016 · first_quarter · Q1
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and FY2017 Agriculture Appropriations.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2015 · fourth_quarter · 4A
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2015 · fourth_quarter · Q4
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2015 · third_quarter · Q3
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2015 · second_quarter · Q2
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2015 · first_quarter · Q1
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; 21st Century Cures Initiative; the regulation and oversight of clinical laboratories; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Medicare reimbursement under the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including cost-sharing for clinical laboratory services under Part B; narrowing the Medicare in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; and S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · fourth_quarter · Q4
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, and H.R. 2914, the Promoting Integrity in Medicare Act of 2014.
Policies affecting reimbursement and regulation of clinical laboratories.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · third_quarter · Q3
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
TRICARE rules affecting beneficiary access to clinical laboratory services, especially molecular diagnostics. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · second_quarter · Q2
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · first_quarter · Q1
TRICARE rules affecting beneficiary access to clinical laboratory services.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · second_quarter · 2A
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · fourth_quarter · Q4
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
TRICARE coverage of molecular pathology tests.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · third_quarter · Q3
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · second_quarter · Q2
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · first_quarter · Q1
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; impact of data privacy proposals on HIPAA compliance and laboratory operations; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. Saving Access to Laboratory Services Act H.R. 8188/S. 4449, VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, Telehealth Extension and Evaluation Act S. 3593, PREVENT Pandemics Act S. 3799.
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises; HRSA COVID-19 Uninsured Test and Vaccine Fund; issues related to validation, deployment, and reimbursement for testing to address 2022 Monkeypox outbreak. VALID Act H.R. 4128/S. 2209, Food and Drug Administration Safety and Landmark Advancements Act S. 4348, Food and Drug Amendments of 2022 H.R. 7667, American Data Privacy and Protection Act H.R. 8152, COVID Supplemental Appropriations Act 2022 H.R. 7007, PREVENT Pandemics Act S. 3799.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93), H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act. .
COVID-19 test coverage and reimbursement
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes, P.L. 117-103 FY2022 Consolidated Appropriations Act, H.R. 7007 COVID Supplemental Appropriations Act, 2022, S. 3593 Telehealth Extension and Evaluation Act, S. 3799 PREVENT Pandemics Act.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
COVID-19 test coverage and reimbursement
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93). H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act, H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 4128/S. 2209 - VALID Act of 2021, H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, H.R.2144 - Access to Genetic Counselor Services Act of 2021, S.1744 - Genomics Data Security Act, S.1260 - United States Innovation and Competition Act of 2021, H.R.2731 - Endless Frontier Act
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021 H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 4128/S. 2209 - VALID Act of 2021, H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, H.R.2144 - Access to Genetic Counselor Services Act of 2021, S.1744 - Genomics Data Security Act, S.1260 - United States Innovation and Competition Act of 2021, H.R.2731 - Endless Frontier Act
COVID-19 test coverage and reimbursement
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021 H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
COVID-19 test coverage and reimbursement
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93). H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act, H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 4128/S. 2209 - VALID Act of 2021, H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, H.R.2144 - Access to Genetic Counselor Services Act of 2021, S.1744 - Genomics Data Security Act, S.1260 - United States Innovation and Competition Act of 2021, H.R.2731 - Endless Frontier Act
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021, H.R. 4128/S. 2209 - VALID Act of 2021, H.Con.Res.11 - Establishing the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, S.Con.Res.5 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, H.R.2144 - Access to Genetic Counselor Services Act of 2021, S.1744 - Genomics Data Security Act, S.1260 - United States Innovation and Competition Act of 2021, H.R.2731 - Endless Frontier Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021.
Reimbursement and coverage issues for and related to clinical laboratory services, including COVID-19 test coverage and reimbursement; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act, H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93). H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act, H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021.
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R.1319 - American Rescue Plan Act of 2021, S.674 - Public Health Infrastructure Saves Lives Act H.R.1848 - To rebuild and modernize the Nation's infrastructure to expand access to broadband and Next Generation 9-1-1, rehabilitate drinking water infrastructure, modernize the electric grid and energy supply infrastructure, redevelop brownfields, strengthen health care infrastructure, create jobs, and protect public health and the environment, and for other purposes, H.R.1818 - To authorize the Secretary of Health and Human Services to award grants to States and political subdivisions of States to support the improvement, renovation, or modernization of infrastructure at clinical laboratories that will help to improve SARS-CoV-2 and COVID-19 testing and response activities, including the expansion and enhancement of testing capacity at such laboratories, H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes, H.R.791 - Tracking COVID-19 Variants Act, S.236 - Tracking COVID-19 Variants Act, H.R.533 - Stop COVID-19 Test Surprise Medical Bills Act of 2021.
COVID-19 test coverage and reimbursement
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act, H.R.133 Consolidated Appropriations Act, 2021, H.R.8900 Further Continuing Appropriations Act, 2021, and Other Extensions Act, H.R.1520 Further Extension of Continuing Appropriations Act, 2021, H.R. 925 Updated Heroes Act, H.R.8496 SPEEDY COVID-19 Tests Act, S.4198 Affordable Coronavirus Testing Act, S.4740 Public Health Infrastructure Saves Lives Act, H.R.8505 To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes., H.R.8702 Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020.
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act, H.R.133 Consolidated Appropriations Act, 2021, H.R.8900 Further Continuing Appropriations Act, 2021, and Other Extensions Act, H.R.1520 Further Extension of Continuing Appropriations Act, 2021, H.R. 925 Updated Heroes Act, H.R.8496 SPEEDY COVID-19 Tests Act, S.4198 Affordable Coronavirus Testing Act, S.4740 Public Health Infrastructure Saves Lives Act, H.R.8505 To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes., H.R.8702 Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.133 Consolidated Appropriations Act, 2021, H.R.8900 Further Continuing Appropriations Act, 2021, and Other Extensions Act, H.R.1520 Further Extension of Continuing Appropriations Act, 2021, H.R. 925 Updated Heroes Act, H.R.8496 SPEEDY COVID-19 Tests Act, S.4198 Affordable Coronavirus Testing Act, S.4740 Public Health Infrastructure Saves Lives Act, H.R.8505 To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes., H.R.8702 Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020.
surprise billing issues relating to clinical laboratory and ancillary providers, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019.COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act, H.R.133 Consolidated Appropriations Act, 2021, H.R.8900 Further Continuing Appropriations Act, 2021, and Other Extensions Act, H.R.1520 Further Extension of Continuing Appropriations Act, 2021, H.R. 925 Updated Heroes Act, H.R.8496 SPEEDY COVID-19 Tests Act, S.4198 Affordable Coronavirus Testing Act, S.4740 Public Health Infrastructure Saves Lives Act, H.R.8505 To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes., H.R.8702 Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020.
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act, H.R.133 Consolidated Appropriations Act, 2021, H.R.8900 Further Continuing Appropriations Act, 2021, and Other Extensions Act, H.R.1520 Further Extension of Continuing Appropriations Act, 2021.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
surprise billing issues relating to clinical laboratory and ancillary providers, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019.COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act.
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act.
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act.
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021, H.R.7615 - To provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, H.R.7658 - To provide a payroll tax credit for certain costs of providing employees with testing for COVID-19, S.4214 - A bill to provide a payroll tax credit for certain expenses associated with protecting employees from COVID-19, S.4198 - Affordable Coronavirus Testing Act, H.R. 925 - Updated Heroes Act, S.178 - Uighur Intervention and Global Humanitarian Unified Response Act of 2019, S.4318 - American Workers, Families, and Employers Assistance Act, S.4322 - Safely Back to School and Back to Work Act, S.4740 - Public Health Infrastructure Saves Lives Act, H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.
surprise billing issues relating to clinical laboratory and ancillary providers, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019.COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548), PL 116-139 Paycheck Protection Program and Health Care Enhancement Act, H.R.6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R.6585 - Equitable Data Collection and Disclosure on COVID-19 Act, S.3850 - Equitable Data Collection and Disclosure on COVID-19 Act, S.4198 - A bill to require health plans to provide coverage for COVID-19 serology testing, H.R.7667 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021, H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021, H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, Vice President of the U.S., White House Office
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548).
surprise billing issues relating to clinical laboratory and ancillary providers, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019.COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548).
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548).
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548).
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020. COVID-19 Pandemic Crisis Response, including COVID-19 laboratory capacity and testing, PL 116-123 Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, PL 116-127 Families First Coronavirus Response Act, PL 116-136 Coronavirus AID, Relief, and Economic Security Act (CARES Act/H.R. 748/S.3548).
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, Vice President of the U.S., White House Office
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
surprise billing issues relating to clinical laboratory and ancillary providers, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019.
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020.
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; H.R. 3584/S. 3049 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act, H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019, H.R. 1158 Consolidated Appropriations Act, 2020, H.R. 1865 Further Consolidated Appropriations Act, 2020.
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, White House Office
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act.
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories, surprise billing issues relating to clinical laboratory and ancillary providers. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act.
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services and pharmacogenetic testing; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); National Diabetes Prevention Program; Anti-Kickback Law relating to clinical laboratories. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services; SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020, H.R. 4378 Continuing Appropriations Act, 2020, and Health Extenders Act.
surprise billing issues relating to clinical laboratory and ancillary providers, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020.
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 269 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, S. 1379 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, H.R. 3055 Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271), H.R. 3584 Laboratory Access for Beneficiaries Act, H.R. 3630 No Surprises Act, S. 1895 Lower Health Care Costs Act, S. 1531 Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1266 Protecting Patients from Surprise Medical Bills Act, H.R. 3502 Protecting People from Surprise Medical Bills Act, H.R. 861 End Surprise Billing Act of 2019, H.R. 2328 Reauthorizing and Extending Americas Community Health Act, H.R. 3107 Improving Seniors' Timely Access to Care Act of 2019, H.R. 2143 Promoting Integrity in Medicare Act of 2019, H.R. 2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, White House Office
SUPPORT for Patients and Communities Act (PL 115-271), Anti-Kickback Law relating to clinical laboratories
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271).
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271).
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act discussion draft and Verifying Accurate, Leading-edge IVCT Development Act discussion draft; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2020; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2020; Medicare reimbursement of clinical laboratory services;SUPPORT for Patients and Communities Act (PL 115-271).
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, White House Office
SUPPORT for Patients and Communities Act (PL 115-271); role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion; Anti-Kickback Law relating to clinical laboratories
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Anti-Kickback Law relating to clinical laboratories. Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion, SUPPORT for Patients and Communities Act (PL 115-271).
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion; application of anti-kickback laws to clinical laboratories
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion; application of anti-kickback laws to clinical laboratories
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
regulation and oversight of clinical laboratories, including laboratory developed test services; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6/H.R. 34, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.; P.L. 114-223, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2017, and Zika Response Preparedness Act; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; FY2017 Agriculture Appropriations; H.R. 5054, Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017; and S. 2956 Agriculture, Rural Development, FDA, and Related Appropriations Act of 2017.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93)and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.Con.Res.27, establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; the regulation and oversight of clinical laboratories; H.Con.Res.27 Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11, Setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2014; 21st Century Cures Initiative; and the regulation and oversight of clinical laboratories.
TRICARE rules affecting beneficiary access to clinical laboratory services, especially molecular diagnostics. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2014; 21st Century Cures Initiative; and the regulation and oversight of clinical laboratories.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
TRICARE rules affecting beneficiary access to clinical laboratory services. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law. TRICARE rules affecting beneficiary access to clinical laboratory services.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), President of the U.S., SENATE
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), President of the U.S., SENATE
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), President of the U.S., SENATE